Capha Pharmaceuticals Inc.
FPSUF
$0.00
$0.000.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -29.25% | -34.74% | -36.21% | -14.29% | 15.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.30% | -35.42% | -36.21% | -15.04% | 15.22% |
| Operating Income | 28.30% | 35.42% | 36.21% | 15.04% | -15.22% |
| Income Before Tax | 27.89% | 45.13% | 2.78% | 22.67% | -34.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 27.89% | 45.13% | 2.78% | 22.67% | -34.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.89% | 45.13% | 2.78% | 22.67% | -34.86% |
| EBIT | 28.30% | 35.42% | 36.21% | 15.04% | -15.22% |
| EBITDA | 29.25% | 34.74% | 36.21% | 14.29% | -15.22% |
| EPS Basic | 0.00% | 50.00% | 0.00% | 0.00% | 0.00% |
| Normalized Basic EPS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS Diluted | 0.00% | 50.00% | 0.00% | 0.00% | 0.00% |
| Normalized Diluted EPS | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |